Old or new antihypertensive drugs? Consequences from "ALLHAT";Alte oder neue antihypertensiva? Konsequenzen aus "ALLHAT"

Deutsche Medizinische Wochenschrift

Volumn 128, Issue 5, 2003, Pages 214-216

  Düsing, Rainer ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; CHLORTALIDONE; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; HYDRALAZINE; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; NEW DRUG; RESERPINE; THIAZIDE DIURETIC AGENT; VALSARTAN; VASODILATOR AGENT;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG INDICATION; HUMAN; HYPERTENSION; NOTE; PRIMARY PREVENTION;

AGED; AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CHLORTHALIDONE; CLINICAL TRIALS; DIURETICS; DOXAZOSIN; FEMALE; HUMANS; HYPERTENSION; LISINOPRIL; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 0037474184     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-36980     Document Type: Note

References (12)

1. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting-enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288: 2981-2997
2. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensiven patients randomised to doxazosin vs chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000; 283: 1967-1975
3. Davis BR, Cutler JA, Furberg CD et al. Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Ann Intern Med 2002; 137: 313-320
4. Appel LJ. The verdict from ALLHAT - thiazide diuretics are the preferred initial therapy for hypertension. JAMA 2002: 288: 3039-3042
5. WHO-ISH Hypertension Guidelines Committee, 1999 World Health Organization. International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-183
6. Sever PS, Dahlöf B et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian cardiac outcomes trial. ASCOT investigators. J Hypertens 2001; 19: 1139-1147
7. Hansson L, Lindholm LH, Niskanen L et al. for the Captopril Primary Prevention Project (CAPPP) study group. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Primary Prevention Project (CAPPP). Lancet 1999: 353: 611-616
8. Hansson L, Lindholm LH, Ekbom T et al. for the STOP-Hypertension-2 study group. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-1756
9. Dahlöf B, Devereux RB, Kjeldsen SE et al. The LIFE Study Group. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003
10. Lindholm LH, Ibsen H, Dahlöf B et al. The LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-1010
11. Kjeldsen SE, Dahlöf B, Devereux RB et al. LIFE Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a losartan intervention for endpoint reduction (LIFE) substudy. JAMA 2002; 288: 1491-1498
12. Mann J, Julius S. The valsartan antihypertensive long-term use evaluation (VALUE) trial of cardiovascular events in hypertension: Rationale and design. Blood Press 1998; 7: 176-183